Alnylam Pharmaceuticals Inc

NASDAQ:ALNY  
200.00
-9.39 (-4.48%)
4:00:07 PM EDT: $199.65 -0.35 (-0.18%)
Products, Regulatory, Earnings Announcements

Alnylam Reports Positive Results From Phase 2 Study Of Investigational Cemdisiran For Treatment Of IgA Nephropathy

Published: 08/29/2022 12:29 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Alnylam Reports Positive Results From Phase 2 Study of Investigational Cemdisiran for Treatment of Iga Nephropathy.
Alnylam Pharmaceuticals Inc - Consistent Proteinuria Reduction Seen With Secondary Endpoints.
Alnylam Pharmaceuticals Inc - Cemdisiran Was Generally Well-tolerated in Patients With Iga Nephropathy.
Alnylam Pharmaceuticals Inc - There Were No Drug-related Serious Or Severe Aes.
Revenue is expected to be $293.19 Million
Adjusted EPS is expected to be -$1.75

Next Quarter Revenue Guidance is expected to be $334.72 Million
Next Quarter EPS Guidance is expected to be -$1.64

More details on our Analysts Page.